These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pathological Circulating Factors in Moyamoya Disease. Fang YC; Wei LF; Hu CJ; Tu YK Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567654 [TBL] [Abstract][Full Text] [Related]
4. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Fujimura M; Watanabe M; Narisawa A; Shimizu H; Tominaga T Surg Neurol; 2009 Nov; 72(5):476-80; discussion 480. PubMed ID: 19147196 [TBL] [Abstract][Full Text] [Related]
5. Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease. Blecharz KG; Frey D; Schenkel T; Prinz V; Bedini G; Krug SM; Czabanka M; Wagner J; Fromm M; Bersano A; Vajkoczy P J Cereb Blood Flow Metab; 2017 Apr; 37(4):1527-1539. PubMed ID: 27381827 [TBL] [Abstract][Full Text] [Related]
6. Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease. Bang OY; Chung JW; Kim SJ; Oh MJ; Kim SY; Cho YH; Cha J; Yeon JY; Kim KH; Kim GM; Chung CS; Lee KH; Ki CS; Jeon P; Kim JS; Hong SC; Moon GJ Int J Stroke; 2016 Dec; 11(9):999-1008. PubMed ID: 27462098 [TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases. Hu W; Jiang W; Ye L; Tian Y; Shen B; Wang K Sci Rep; 2017 Jul; 7(1):5452. PubMed ID: 28710384 [TBL] [Abstract][Full Text] [Related]
8. Increase of Circulating Endothelial Progenitor Cells and Released Angiogenic Factors in Children with Moyamoya Arteriopathy. Gorla G; Carrozzini T; Pollaci G; Potenza A; Nava S; Acerbi F; Ferroli P; Esposito S; Saletti V; Ciusani E; Zulueta A; Parati EA; Bersano A; Gatti L; Vetrano IG Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674749 [TBL] [Abstract][Full Text] [Related]
9. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. Hojo M; Hoshimaru M; Miyamoto S; Taki W; Nagata I; Asahi M; Matsuura N; Ishizaki R; Kikuchi H; Hashimoto N J Neurosurg; 1998 Oct; 89(4):623-9. PubMed ID: 9761057 [TBL] [Abstract][Full Text] [Related]
10. [Plasma fibronectin level in patients with moyamoya disease]. Sasaki O; Tanaka R; Koike T; Takeuchi S; Takizawa T; Ishi R; Arai H No To Shinkei; 1987 Nov; 39(11):1069-73. PubMed ID: 3442638 [TBL] [Abstract][Full Text] [Related]
11. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Rafat N; Beck GCh; Peña-Tapia PG; Schmiedek P; Vajkoczy P Stroke; 2009 Feb; 40(2):432-8. PubMed ID: 19095988 [TBL] [Abstract][Full Text] [Related]
12. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. Kang HS; Kim JH; Phi JH; Kim YY; Kim JE; Wang KC; Cho BK; Kim SK J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):673-8. PubMed ID: 19965844 [TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Vascular Endothelial Growth Factor-A Jiang H; Toscano JF; Schiraldi M; Song SS; Schlick KH; Dumitrascu OM; Liou R; Lyden PD; Pan J; Zhan R; Saver JL; Gonzalez NR J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):360-368. PubMed ID: 30392834 [TBL] [Abstract][Full Text] [Related]
14. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. Ahel J; Lehner A; Vogel A; Schleiffer A; Meinhart A; Haselbach D; Clausen T Elife; 2020 Jun; 9():. PubMed ID: 32573437 [TBL] [Abstract][Full Text] [Related]
15. Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line. Uchino H; Ito M; Kazumata K; Hama Y; Hamauchi S; Terasaka S; Sasaki H; Houkin K BMC Med Genomics; 2018 Aug; 11(1):72. PubMed ID: 30157848 [TBL] [Abstract][Full Text] [Related]